by In2Pharma | Feb 16, 2022 | News
The Netherlands Medicinal Product Quality Defects and Shortages on the Dutch Market should be reported through the “Meldpunt geneesmiddelentekorten en -defecten”. As of 01 January 2022, the Medicines Evaluation Board (MEB) and the Inspectorate (IGJ) have implemented...
by In2Pharma | May 6, 2021 | News
Europe An important piece of the new Pharmaceutical Strategy adopted in November 2020 by the von der Leyen Commission is represented by the structured dialogue with the actors of the pharmaceuticals manufacturing chain in order to better identify causes and drivers of...
